Related references
Note: Only part of the references are listed.A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial
Thomas J. Povsic et al.
AMERICAN HEART JOURNAL (2011)
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
Ph. Gabriel Steg et al.
EUROPEAN HEART JOURNAL (2011)
Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy
Thomas J. Povsic et al.
EUROPEAN HEART JOURNAL (2011)
Radial Artery Access as a Predictor of Increased Radiation Exposure During a Diagnostic Cardiac Catheterization Procedure
Mathew Mercuri et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2011)
Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design
T. J. Povsic et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial
Sanjit S. Jolly et al.
LANCET (2011)
Meta-analysis of randomized trials on the efficacy of vascular closure devices after diagnostic angiography and angioplasty
Fausto Biancari et al.
AMERICAN HEART JOURNAL (2010)
First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention
Mauricio G. Cohen et al.
CIRCULATION (2010)
Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics
Richard C. Becker et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine
Thomas J. Povsic et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2010)
Impact of Anticoagulation Regimens on Sheath Management and Bleeding in Patients Undergoing Elective Percutaneous Coronary Intervention in the STEEPLE Trial
Richard Gallo et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2009)
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial
Marc S. Sabatine et al.
LANCET (2009)
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease
Mark Y. Chan et al.
CIRCULATION (2008)
Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study
B. I. Eriksson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII)
G. J. Miller et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor
M. Y. Chan et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Bivalirudin during primary PCI in acute myocardial infarction
Gregg W. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout
John S. Sundy et al.
ARTHRITIS AND RHEUMATISM (2007)
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal
Warren J. Cantor et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2007)
Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and YII
Carine J. M. Doggen et al.
BLOOD (2006)
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology - A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity
Christopher K. Dyke et al.
CIRCULATION (2006)
Bivalirudin for patients with acute coronary syndromes
Gregg W. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase
NJ Ganson et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Arterial puncture closing devices compared with standard manual compression after cardiac catheterization -: Systematic review and meta-analysis
M Koreny et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Share Paper
